EU pay-for-delay ruling ‘prevents cooperation and market sharing’
The recent decision in Generics v Competition and Markets Authority from the CJEU is too restrictive and will result in higher litigation costs, say pharma sources
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
